In an inpatient detox unit, which benzodiazepine is most appropriate for managing alcohol withdrawal symptoms in a patient with comorbid hepatic disease?

Choice A reason: Lorazepam is preferred in patients with hepatic impairment because it is metabolized through conjugation rather than oxidation. This makes it safer and more predictable in individuals with liver dysfunction. It is effective in managing alcohol withdrawal symptoms without accumulating toxic metabolites. Choice B reason: Chlordiazepoxide is metabolized hepatically and has a long half-life. In patients with liver disease, it can accumulate and increase the risk of sedation and toxicity. It is generally avoided in hepatic impairment. Choice C reason: Clonazepam is also metabolized by the liver and has a long half-life. It is not typically used for alcohol withdrawal and poses risks in hepatic disease. Choice D reason: Diazepam is highly lipophilic and extensively metabolized by the liver. It has active metabolites that can accumulate in hepatic dysfunction, increasing the risk of oversedation and respiratory depression. It is not recommended in this context.